Treatment of acute opioid withdrawal with ibogaine

Am J Addict. Summer 1999;8(3):234-42. doi: 10.1080/105504999305848.

Abstract

Ibogaine is an alkaloid with putative effect in acute opioid withdrawal. Thirty-three cases of treatments for the indication of opioid detoxification performed in non-medical settings under open label conditions are summarized involving an average daily use of heroin of .64 +/- .50 grams, primarily by the intravenous route. Resolution of the signs of opioid withdrawal without further drug seeking behavior was observed within 24 hours in 25 patients and was sustained throughout the 72-hour period of posttreatment observation. Other outcomes included drug seeking behavior without withdrawal signs (4 patients), drug abstinence with attenuated withdrawal signs (2 patients), drug seeking behavior with continued withdrawal signs (1 patient), and one fatality possibly involving surreptitious heroin use. The reported effectiveness of ibogaine in this series suggests the need for systematic investigation in a conventional clinical research setting.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Female
  • Hallucinogens / administration & dosage
  • Hallucinogens / pharmacology
  • Hallucinogens / therapeutic use*
  • Heroin Dependence / drug therapy*
  • Humans
  • Ibogaine / administration & dosage
  • Ibogaine / pharmacology
  • Ibogaine / therapeutic use*
  • Injections, Intravenous
  • Male
  • Substance Withdrawal Syndrome / drug therapy
  • Treatment Outcome

Substances

  • Hallucinogens
  • Ibogaine